The complex interplay between fitness, genetics, lifestyle, and inflammation in the pathogenesis of coronary atherosclerosis: lessons from the Amazon rainforest
- PMID: 30948957
- PMCID: PMC6439945
- DOI: 10.1093/eurheartj/suz030
The complex interplay between fitness, genetics, lifestyle, and inflammation in the pathogenesis of coronary atherosclerosis: lessons from the Amazon rainforest
Abstract
Far from only being a modern disease, atherosclerosis has also been reported also in ancient civilizations, as shown in some studies conducted on Mummies from different latitudes. Conventional cardiovascular (CV) risk factors can explain more than 90% of the attributable risk of coronary artery disease (CAD). In this regard, Tsimane Aborigenous of Amazon rainforest, conducting a subsistence lifestyle with low prevalence of CV risk factors, present the lowest reported prevalence of CAD in the world, despite an elevated inflammatory burden. Experimental and clinical studies have supported the theory that other factors, like genetics and inflammation, are involved in atherosclerosis. Indeed, a large clinical randomized study (CANTOS trial) tested the anti-inflammatory properties of canakinumab, and provided the first evidence to support the 'inflammation hypothesis'. Another field of research, based on Mendelian randomization studies, supports the appealing hypothesis that correcting CV risk factors earlier in life, may prevent or delay the progression of CAD. All these data prove that atherosclerosis is the expression of a complex, dynamic, and continuous interaction between environment and genetics that begins at conception and continues through adulthood.
Keywords: Atherosclerosis; Environment; Genetics; Inflammation.
References
-
- Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L.. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–952. - PubMed
-
- Kaplan H, Thompson RC, Trumble BC, Wann LS, Allam AH, Beheim B, Frohlich B, Sutherland ML, Sutherland JD, Stieglitz J, Rodriguez DE, Michalik DE, Rowan CJ, Lombardi GP, Bedi R, Garcia AR, Min JK, Narula J, Finch CE, Gurven M, Thomas GS.. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet 2017;389:1730–1739. - PMC - PubMed
-
- Allam AH, Thompson RC, Wann LS, Miyamoto MI, Nur el-Din A. e-H, el-Maksoud GA, Al-Tohamy Soliman M, Badr I, el-Rahman Amer HA, Sutherland ML, Sutherland JD, Thomas GS.. Atherosclerosis in ancient Egyptian Mummies. The Horus Study . JACC Cardiovasc Imaging 2011;4:315–327. - PubMed
-
- Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, Soliman MA-T, Frohlich B, Mininberg DT, Monge JM, Vallodolid CM, Cox SL, Abd el-Maksoud G, Badr I, Miyamoto MI, el-Halim Nur el-Din A, Narula J, Finch CE, Thomas GS.. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet 2013;381:1211–1222. - PubMed
-
- Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ.. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–1131. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous